• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

EVEROLIMUS Drug Record

  • Summary
  • Interactions
  • Claims
  • EVEROLIMUS chembl:CHEMBL1908360 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    SDZ-RAD
    AFINITOR DISPERZ
    ZORTRESS
    RAD001
    RAD 666
    RAD-666
    AFINITOR
    CERTICAN
    RAD-001
    VOTUBIA
    EVEROLIMUS
    42-O-(2-HYDROXYETHYL)RAPAMYCIN
    40-O-(2-HYDROXYETHYL)-RAPAMYCIN
    chembl:CHEMBL1908360
    rxcui:141704
    drugbank:01590
    chemidplus:159351-69-6
    pubchem.compound:6442177

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications immunosuppressant
    FDA Approval Pancreatic, gastrointestinal, or lung origin neuroendocrine tumors; Renal cell carcinoma, Subependymal giant cell astrocytoma associated with tuberous sclerosis, Breast cancer (ER+, HER2-)
    Notes rapalogue
    Drug Class Kinase Inhibitors
    Drug Class immunosuppressive agents
    Year of Approval 2009
    (13 More Sources)

    Publications:

    Powles et al., 2016, Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma., J. Clin. Oncol.
    Klümpen et al., 2011, mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome., J. Clin. Oncol.
    Donovan et al., 2016, Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy., CNS Oncol
    Carita et al., 2016, Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma., Oncotarget
    Kato et al., 2017, RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients., Clin. Cancer Res.
    Schneider et al., 2015, Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial., Int J Endocrinol
    Wong CP et al., 2015, Bisleuconothine A Induces Autophagosome Formation by Interfering with AKT-mTOR Signaling Pathway., J Nat Prod
    Salomé C et al., 2014, Benzofuran derivatives as anticancer inhibitors of mTOR signaling., Eur J Med Chem
    Voss et al., 2014, Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy., Clin. Cancer Res.
    Wagle et al., 2014, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib., Cancer Discov
    Lim et al., 2016, Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus., Oncotarget
    Raushenbakh et al., 1976, [Induction of tyrosine aminotransferase by blastomogenic metabolites of tryptophan and tyrosine]., Biull Eksp Biol Med
    Silen et al., 1975, Acid-base balance in amphibian gastric mucosa., Am. J. Physiol.
    Wagle et al., 2014, Response and acquired resistance to everolimus in anaplastic thyroid cancer., N. Engl. J. Med.
    Ettenger et al., 2008, Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year., Pediatr Transplant
    Teachey et al., 2009, Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies., Br. J. Haematol.
    Coppin, 2010, Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib., Biologics
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    George et al., 2009, Role of everolimus in the treatment of renal cell carcinoma., Ther Clin Risk Manag
    Rostaing et al., mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?, J. Nephrol.
    Albert et al., 2010, New inhibitors of the mammalian target of rapamycin signaling pathway for cancer., Expert Opin Investig Drugs
    Stjepanovic N et al., 2015, Elucidating the genomic landscape of breast cancer: how will this affect treatment?, Pharmacogenomics
    Di Nicolantonio et al., 2010, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus., J. Clin. Invest.
    Mohseni et al., 2010, PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001., J. Clin. Invest.
    Seront et al., 2012, Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers., Ann. Oncol.
    Kim et al., 2017, Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy., BMC Cancer
    Shoji et al., 2012, Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas., PLoS ONE
    Weigelt et al., 2011, PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs., Oncogene
    André et al., 2016, Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3., J. Clin. Oncol.
    Seront et al., 2013, PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation., Br. J. Cancer
    Templeton et al., 2013, Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)., Eur. Urol.
    Kiessling et al., 2015, Mutant HRAS as novel target for MEK and mTOR inhibitors., Oncotarget
    André et al., 2014, Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet Oncol.
    Andre et al., 2010, Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab., J. Clin. Oncol.
    Jerusalem et al., 2011, Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer., Breast Cancer Res. Treat.
    Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
    Kiessling et al., 2016, Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma., PLoS ONE
    Gibson et al., 2017, Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer., Clin. Cancer Res.
    Olow et al., 2016, BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas., Clin. Cancer Res.
    Jain P et al., 2017, Overcoming resistance to single-agent therapy for oncogenic <i>BRAF</i> gene fusions <i>via</i> combinatorial targeting of MAPK and PI3K/mTOR signaling pathways., Oncotarget
    Hsieh et al., 2017, Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma., Eur. Urol.
    Basho et al., 2017, Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab., JAMA Oncol
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
    Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
    Iyer et al., 2012, Genome sequencing identifies a basis for everolimus sensitivity., Science
    Franz et al., 2013, Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial., Lancet
    Mo et al., 2016, mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer., Clin. Cancer Res.
    Nakamura M et al., 2013, [A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents]., Hinyokika Kiyo
    Goutagny et al., 2015, Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas., J. Neurooncol.
    Watkin et al., 1989, Sequential combination chemotherapy and radiotherapy in locally advanced non-small cell carcinoma of the bronchus., Respir Med
    Karajannis et al., 2014, Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas., Neuro-oncology
    Guglielmelli et al., 2011, Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis., Blood
    Lesche D et al., 2015, Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation., Clin Transplant
    Schoeppler KE et al., 2014, The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients., Clin Transplant
  • EVEROLIMUS   TSC2

    Interaction Score: 6.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25295501 23158522


    Sources:
    CIViC OncoKB

  • EVEROLIMUS   TSC1

    Interaction Score: 4.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22923433 26859683 11010 2015 24622468 23158522


    Sources:
    CIViC OncoKB

  • EVEROLIMUS   KDM5C

    Interaction Score: 1.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27751729


    Sources:
    CIViC

  • EVEROLIMUS   FLCN

    Interaction Score: 1.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23995526


    Sources:
    CIViC

  • EVEROLIMUS   NF2

    Interaction Score: 1.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25567352 2556735 24311643


    Sources:
    CIViC

  • EVEROLIMUS   BAP1

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27751729


    Sources:
    CIViC

  • EVEROLIMUS   FKBP1A

    Interaction Score: 0.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction FK506-binding protein 1A inhibitor
    Direct Interaction yes

    PMIDs:
    24836070


    Sources:
    DTC ClearityFoundationClinicalTrial ChemblInteractions

  • EVEROLIMUS   GNA11

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AEB071 + Everolimus
    Indication/Tumor Type uveal melanoma
    Response Type predicted – sensitive

    PMIDs:
    27507190


    Sources:
    JAX-CKB

  • EVEROLIMUS   RPTOR

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • EVEROLIMUS   PBRM1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27751729


    Sources:
    CIViC

  • EVEROLIMUS   MTOR

    Interaction Score: 0.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Variant Effect gain-of-function
    Pathway activation
    Clinical Status case report

    PMIDs:
    26176165 24836070 24622468 24625776 26859683 11010 2015 25295501 18466433 19344392 20531964 11752352 19774211 20155724 20569080 25893859


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND DoCM CIViC MyCancerGenomeClinicalTrial PharmGKB TTD OncoKB

  • EVEROLIMUS   VHL

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type renal cell carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    26951309


    Sources:
    JAX-CKB CIViC

  • EVEROLIMUS   MPL

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type myelofibrosis
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    21725052


    Sources:
    JAX-CKB

  • EVEROLIMUS   STK11

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Clinical Status case report
    Pathway activation
    Variant Effect loss-of-function

    PMIDs:
    21189378 27615706


    Sources:
    JAX-CKB DoCM

  • EVEROLIMUS   GNAQ

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AEB071 + Everolimus
    Indication/Tumor Type uveal melanoma
    Response Type predicted – sensitive

    PMIDs:
    27507190


    Sources:
    JAX-CKB

  • EVEROLIMUS   PTEN

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    20664172 20664174 22473592 28330462 26951309 22662154 21358673 27091708 23989949 23582881


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • EVEROLIMUS   NOTCH1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ribociclib + Everolimus
    Indication/Tumor Type T-cell adult acute lymphocytic leukemia
    Response Type sensitive

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • EVEROLIMUS   RB1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ribociclib + Everolimus
    Indication/Tumor Type T-cell adult acute lymphocytic leukemia
    Response Type sensitive

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • EVEROLIMUS   HRAS

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type urinary bladder cancer
    Response Type predicted – sensitive
    Indication/Tumor Type Advanced Solid Tumor

    PMIDs:
    26544513


    Sources:
    JAX-CKB CIViC

  • EVEROLIMUS   NRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    23629727 26821351


    Sources:
    JAX-CKB CIViC

  • EVEROLIMUS   PIK3CA

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    21358673 27091708 27797976 26951309 27893038 22662154 23629727 20664172 20664174


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • EVEROLIMUS   BRAF

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus + Selumetinib
    Indication/Tumor Type malignant glioma
    Response Type predicted – sensitive

    PMIDs:
    20664172 20664174 23629727 27797976 27217440 29156677


    Sources:
    JAX-CKB CIViC

  • EVEROLIMUS   BRCA2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus + Talazoparib
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    26546619


    Sources:
    JAX-CKB

  • EVEROLIMUS   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant

    PMIDs:
    23629727 22662154 26725216 20664172 20664174


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • EVEROLIMUS   RET

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type thyroid medullary carcinoma
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    27683183 26294908


    Sources:
    JAX-CKB

  • EVEROLIMUS   AKT2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • EVEROLIMUS   AKT3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • EVEROLIMUS   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase III
    Response Type sensitive

    PMIDs:
    24742739 20975068 21107682


    Sources:
    JAX-CKB PharmGKB FDA

  • EVEROLIMUS   FGFR4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • EVEROLIMUS   ATM

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Vandetanib + Everolimus
    Indication/Tumor Type thyroid medullary carcinoma
    Response Type predicted – sensitive

    PMIDs:
    27683183


    Sources:
    JAX-CKB

  • EVEROLIMUS   PIK3R1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • EVEROLIMUS   CYP3A5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26458301 24628014


    Sources:
    PharmGKB

  • EVEROLIMUS   AKT1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase Ib/II
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB MyCancerGenomeClinicalTrial

  • EVEROLIMUS   BRCA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    combination therapy Olaparib + Everolimus
    Indication/Tumor Type triple-receptor negative breast cancer

    PMIDs:
    26546619


    Sources:
    JAX-CKB

  • EVEROLIMUS   ESR2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • EVEROLIMUS   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus + Pimasertib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    23629727


    Sources:
    JAX-CKB

  • EVEROLIMUS   ESR1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • EVEROLIMUS   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • EVEROLIMUS   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: EVEROLIMUS

    • Version: 20-Jun-2017

    Alternate Names:
    RAD001 Development Name
    EVEROLIMUS Generic Name
    AFINITOR Trade Name

    Drug Info:
    Drug Class Kinase Inhibitors
    Notes rapalogue
    FDA Approval Pancreatic, gastrointestinal, or lung origin neuroendocrine tumors; Renal cell carcinoma, Subependymal giant cell astrocytoma associated with tuberous sclerosis, Breast cancer (ER+, HER2-)

    Publications:

  • TEND: EVEROLIMUS

    • Version: 01-August-2011

    Alternate Names:
    EVEROLIMUS Primary Drug Name

    Drug Info:
    Year of Approval 2009
    Drug Class immunosuppressive agents

    Publications:

  • TdgClinicalTrial: EVEROLIMUS

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications immunosuppressant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: EVEROLIMUS

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1908360 ChEMBL Drug ID

    Drug Info:

    Publications:
    Wong CP et al., 2015, Bisleuconothine A Induces Autophagosome Formation by Interfering with AKT-mTOR Signaling Pathway., J Nat Prod
    Salomé C et al., 2014, Benzofuran derivatives as anticancer inhibitors of mTOR signaling., Eur J Med Chem

  • JAX-CKB: Everolimus

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Powles et al., 2016, Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma., J. Clin. Oncol.
    Schneider et al., 2015, Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial., Int J Endocrinol
    Kato et al., 2017, RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients., Clin. Cancer Res.

  • DoCM: EVEROLIMUS

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Klümpen et al., 2011, mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome., J. Clin. Oncol.
    Wagle et al., 2014, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib., Cancer Discov
    Voss et al., 2014, Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy., Clin. Cancer Res.

  • PharmGKB: everolimus

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Stjepanovic N et al., 2015, Elucidating the genomic landscape of breast cancer: how will this affect treatment?, Pharmacogenomics
    Lesche D et al., 2015, Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation., Clin Transplant
    Schoeppler KE et al., 2014, The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients., Clin Transplant

  • CIViC: EVEROLIMUS

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Iyer et al., 2012, Genome sequencing identifies a basis for everolimus sensitivity., Science
    Franz et al., 2013, Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial., Lancet
    Hsieh et al., 2017, Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma., Eur. Urol.

  • TALC: EVEROLIMUS

    • Version: 12-May-2016

    Alternate Names:
    EVEROLIMUS Primary Drug Name
    EVEROLIMUS Drug Generic Name
    AFINITOR Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Everolimus

    • Version: 2020.06.01

    Alternate Names:
    D0K3QS TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1908360

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1908360

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Everolimus

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: EVEROLIMUS

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: EVEROLIMUS

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Everolimus

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: EVEROLIMUS

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21